BEIJING, June 16 (Reuters) – Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill "very soon," its CEO said on Tuesday, as it moves to catch up with rival Eli Lilly
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)